Email: cspc@cspc.cn
News
News Center
May. 19
2025
CPO301 GRANTED THE THIRD FAST TRACK DESIGNATION BY U.S. FDA FOR THE TREATMENT OF ADULT PATIENTS WITH NSCLC
May. 15
EXCLUSIVE LICENSE AGREEMENT WITH CIPLA USA, INC. FOR IRINOTECAN LIPOSOME INJECTION
May. 12
VONOPRAZAN FUMARATE TABLETS OBTAINS DRUG REGISTRATION APPROVAL
May. 09
SYH2046 TABLETS OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
May. 02
JMT202 (RECOMBINANT FULLY HUMAN ANTI-βKLOTHO MONOCLONAL ANTIBODY DRUG) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Apr. 30
VOLUNTARY ANNOUNCEMENT - PIVOTAL PHASE II/III CLINICAL STUDY OF KN026 MET PRIMARY ENDPOINT OF PROGRESSION-FREE SURVIVAL (PFS) AT INTERIM ANALYSIS
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us
